Special formula may shield At-Risk babies from allergies
NCT ID NCT03489733
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a low-protein, extensively hydrolyzed infant formula with added pre- and probiotics can prevent allergies in babies at high risk. Over 1,200 healthy newborns were given either the special formula or a standard formula during their first months of life. Researchers tracked how many developed atopic dermatitis (eczema) by age one, and will follow them until age six to see long-term effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
extensively hydrolyzed infant formula with pre- and probiotics
What this could lead to
If successful, this could show that a specific infant formula reduces the chance of developing allergies in at-risk babies.
What could go wrong
The study is completed but results are not yet widely confirmed. The effect may be small or not apply to all infants. No serious risks are expected from a standard infant formula.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Estaing
Clermont-Ferrand, France
-
Charité Universitätsmedizin Berlin
Berlin, Germany
-
Clinical Hospital Center "Dr Dragisa Misovic-Dedinje"
Belgrade, Serbia
-
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, Spain
-
Hospital braga
Braga, Portugal
-
Instytut Mikroekologii
Poznan, Poland
-
Klinik für Kinder und Jugendmedizin
Hamm, Germany
-
Klinik für Kinder- und Jugendmedizin Marienhospital gGmbH Wesel
Wesel, Germany
-
Klinik für Kinder- und Jugendmedizin der Ruhruniversität Bochum im St. Josef Hospital
Bochum, Germany
-
Nemocnice Strakonice, a.s.
Strakonice, Czechia
-
Second specialized obstetric and gynecological hospital for active treatment Sheinovo EAD
Sofia, Bulgaria
-
Studienambulanz der pädiatrische Pneumologie und AllergologieKlinik für Kinder- und Jugendmedizin (KKJM)
Frankfurt, Germany
-
Suomen Terveystalo Oy
Tampere, Finland
-
Unità Allergologia-Unità Allergologia-
Roma, Italy